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2Abstract 
Background The anti-epileptic drug vigabatrin is associated with visual field loss (VAVFL) 
and thinning of the peripapillary retinal nerve fibre layer (PPRNFL), thereby implicating retinal 
ganglion cell (RGC) dysfunction. 
Objective The objective of the study was to determine the relationship between the two 
outcomes in order to improve the risk/ benefit analysis of vigabatrin, particularly in those 
unable to undertake perimetry.
Methods A retrospective cross-sectional observational design identified 40 adults who had 
received vigabatrin for refractory seizures and who had undergone a combined protocol of 
perimetry and optical coherence tomography (OCT) of the PPRNFL. Two established models 
successfully applied to other optic neuropathies were used to evaluate, topographically, the 
function-structure relationship for the superior and inferior retinal quadrants.
Results The function-structure relationship for each model was consistent with other optic 
neuropathies. With the first model, PPRNFL thinning, expressed in µm, asymptoted at an 
equivalent visual field loss of worse than approximately -10.0dB, thereby preventing 
assessment of more substantial thinning. The second model overcame the asymptote by 
transforming the outcomes to RGC soma and axon estimates, respectively; the latter were 
linearly related. 
Conclusions Concurrent use of perimetry and OCT, enabling reciprocal validation, is essential 
for the detection and assessment of vigabatrin toxicity. However, OCT affords a limited 
measurement range compared to perimetry: severity cannot be directly assessed when the 
PPRNFL quadrant thickness is less than approximately 65µm, depending upon the type of 
tomographer. This limitation can be overcome by transformation of thickness to remaining 
axons, an outcome requiring input from perimetry.  
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31.0 Introduction 
Vigabatrin was introduced outside of the USA in 1989 as add-on therapy for adults with 
refractory focal seizures and as monotherapy for infantile spasms [1-2]. It gained FDA approval 
for these uses in 2009. The pattern of vigabatrin usage in the USA over the five year period 
ending 2014 has been documented for adults [3] and for infants [4].  
Vigabatrin is associated with irreversible visual field loss (VAVFL) 5-10. The frequency of 
VAVFL in adults, modelled from cross-sectional evidence, increases rapidly in the first two 
years (2kg cumulative dose) of treatment [11-12] and plateaus at 75-80% after approximately 
six years duration (5kg cumulative dose) [12]. The field loss manifests as a bilateral, and 
clinically symmetrical, ‘concentric’ constriction. When present within the central field, the
field loss, by probability analysis of standard automated perimetry (SAP), exhibits a steep sided
bi-nasal annulus which extends, to varying amounts, vertically across the horizontal midline
and also centripetally. In severe manifestations, the field loss is concentric to within
approximately 15º from fixation [8]. 
Vigabatrin is also associated with a thinning of the peripapillary retinal nerve fibre layer 
(PPRNFL) [13-18]. The assessment of the PPRNFL by optical coherence tomography (OCT), 
a rapid, objective and non-invasive imaging technique, yields a characteristic bilateral and 
clinically symmetrical pattern of damage in adults [15-17] and children [18]: namely, superior 
and/ or inferior quadrant thinning, with or without nasal quadrant thinning, and a normal 
temporal quadrant thickness. The temporal quadrant exhibits thinning only in cases of 
concentric field loss within the central field [15]. However, one study has reported that the 
PPRNFL thickness increases with initial exposure to vigabatrin [19] whilst another suggests 
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4that PPRNFL thinning in adults is associated with epilepsy and with anti-epileptic drug 
resistance, in particular [20]. 
The characteristics of the VAVFL and of the concomitant PPRNFL thinning are compatible 
with a subtle nasal [21] or ‘inverse’ [22] optic atrophy, i.e., that sparing the temporal sector of
the optic nerve head which contains the axons from the papillomacular bundle. They are also
compatible with the retinal histology at post mortem of an individual with VAVFL [23].
However, VAVFL is also associated with a reduction in the amplitude of the 30Hz flicker cone
electroretinogram response, thereby implicating the cone pathway [24-25]. 
The function-structure association between the severity of the VAVFL and the extent of the 
PPRNFL thickness has received little attention [14, 16-17]. However, any association is 
potentially confounded by the non-axonal component of OCT reflectance in advanced disease, 
i.e., that arising from glial cells etc., which prevents measurement of the PPRNFL below 
approximately 45μm [26] depending upon the type of tomographer. In addition, any 
topographical variation in the association has not been evaluated. 
The lack of clarity in the relationship between the functional and structural abnormalities in 
vigabatrin toxicity is clinically concerning given the requirement to maintain the balance 
between the optimum treatment of the epilepsy and the prevention of irreversible visual 
dysfunction. Such concern is paramount in the management of infantile spasms, where 
perimetry is not viable until at least a developmental age of eight years [24], and in at least 20-
25% of adults exposed to vigabatrin who are unable to undertake a visual field examination 
reliably [17, 24].  
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5Although various models have been proposed [27], two distinctly different models have gained 
popularity for the description of the function-structure association in diseases involving the 
retinal ganglion cells [28-29]. The model of Hood [28], which is confounded by the non-axonal 
component of OCT reflectance, yields an exponential function in primary open-angle glaucoma 
[30], ischaemic optic neuropathy [31] and optic neuritis [32] between the PPRNFL thickness,
by quadrant, and the mean of the corresponding age-corrected central visual field loss. The
empirically derived model of Harwerth and colleagues [29] compensates for the non-axonal
component of OCT reflectance. It yields a strong linear association in primary open-angle
glaucoma [29] between the estimated number of remaining retinal ganglion cell soma at each
stimulus location, calculated from the central field outcome, and the estimated number of
remaining ganglion cell axons, based upon the PPRNFL thickness derived by OCT, at the
topographically corresponding position of entry into the optic nerve head. Given the
involvement, either as a primary or as a secondary outcome, of the PPRNFL and, thus, the
retinal ganglion cells in the pathogenesis of vigabatrin toxicity, it can be hypothesized that both
models would exhibit a strong topographical function-structure relationship. Such an outcome,
if present, would inform the detection, and assessment of any progression, of the toxicity.
The primary purpose of the study, therefore, was to determine the function-structure 
relationship in vigabatrin toxicity using the models of Hood [28] and Harwerth [29]. The
secondary aim was to determine the associations between the estimated numbers of remaining
ganglion cell soma and axons, derived from the Harwerth model, and the extent of exposure to
vigabatrin. Such outcomes would enable refinement of the continuous risk/ benefit assessment
necessary for patients receiving vigabatrin.
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62.0 Methods 
The study utilized a retrospective cross-sectional observational design. 
2.1 Cohort 
A case series of 40 individuals, who had previously been treated with vigabatrin as add-on 
therapy for refractory seizures, was identified from those attending the Alan Richens Unit of 
the Welsh Epilepsy Centre, University Hospital of Wales, Cardiff, UK. Of these, 30 had focal 
seizures, six generalized and four of unknown onset. All individuals had undergone 
ophthalmological examination and conformed to standard inclusion criteria adopted for studies 
involving perimetry [33], particularly in regard to an absence of visual pathway abnormality 
identified by whole-brain magnetic resonance imaging (MRI) [16] and the ensuing retrograde 
trans-synaptic degeneration of the PPRNFL [34]. They had all completed a reliable outcome 
on at least two occasions to a standardized protocol of perimetry and OCT. 
A second cohort of 11 consecutively presenting normal individuals, who had taken part in a 
separate study which had utilized a similar methodology, was used as a control. They were 
recruited from those attending the Cardiff University Eye Clinic and all conformed to inclusion 
criteria identical to that of the cohort exposed to vigabatrin with the exception that none were 
epileptic and none had undergone whole-brain MRI. The cohort was older than that exposed 
to vigabatrin.  
2.2 Perimetry 
The visual field examinations conformed to the protocol approved by the European Medicines 
Agency for the detection of VAVFL: in this instance, Three Zone age-corrected suprathreshold 
perimetry of the central and peripheral field using the Full Field 135 Point Screening Test and 
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7SAP of the central field using the Central 30-2 Threshold Test and the FASTPAC strategy of 
the Humphrey Field Analyzer 750 (Carl Zeiss, Meditec, Dublin, CA) [35]. 
The normal individuals had all undergone SAP in each eye using the Central 24-2 Threshold 
Test and the SITA Standard strategy of the Humphrey Field Analyzer 750. All had previously 
undertaken perimetry as part of their routine clinical care. 
Inclusion criteria for the reliability of the outcome of the visual field examination comprised 
≤15% incorrect responses to the false-positive catch trials; ≤20% incorrect responses to the 
fixation loss catch trials and/ or good quality outcomes to the gaze tracking; and ≤30% incorrect 
responses to the false-negative catch trials, the tolerance widened with increase in severity of 
the field loss [36].  
The visual fields were selected from the most recent visit at which the reliability criteria had 
been met. They were reviewed at the end of the inclusion phase, masked to the given cohort, 
in random order by one of the authors (JMW) who is highly experienced in interpreting the 
visual fields from patients exposed to vigabatrin [8-9, 35].  The outcome was classified on the 
appearance of, and the consistency between, the peripheral and the central fields. 
2.3 Optical Coherence Tomography 
Measurement of the PPRNFL thickness had been undertaken using the standard 3.4 Scan 
protocol of the StratusOCT (Carl Zeiss, Meditec, Dublin, CA). The pupils were dilated, if 
necessary, with one drop of 0.5% tropicamide and one drop of 2.5% phenylephrine 
hydrochloride. The polarization and Z-axis offset were optimized to gain maximum reflection 
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8of the signal. Between three and seven images were retained for each individual. All retained 
images were free from blink or movement artefacts and had a signal to noise ratio of ≥ 33dB.  
The OCT images from the visit corresponding to that selected for the visual field outcome were 
reviewed in random order by two authors (SA and CK), independently of one another. Both 
authors were masked to the cohort and to the outcome of the perimetry. The images which 
possessed the optimal placement of the scan centre, compatible with the maximum signal to 
noise ratio, were selected for each individual. The PPRNL thickness was calculated as the mean 
of the thicknesses from the retained images.  
2.4 Modelling 
2.4.1 Hood model
The Hood model was separately constructed for the superior and the inferior quadrants (Online 
Supporting Information; Appendix 1). Briefly, the quadrant PPRNFL thickness and the mean 
of the Total Deviation values (defined as the measured differential light sensitivity at the given 
location minus the age-corrected normal value) across the stimulus locations within the 
corresponding quadrant of the central field were obtained for each individual. The ensuing 
association was described by the exponential function which is defined by two parameters: the 
quadrant mean Total Deviation of each normal individual and the quadrant PPRNFL 
thicknesses of those individuals exposed to vigabatrin with a Total Deviation of worse than       
-10dB.  
2.4.2 Harworth model 
The Harworth model was separately constructed for the superior and the inferior quadrants 
(Online Supporting Information; Appendix 2). Briefly, the number of remaining ganglion cell 
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9soma at each stimulus location within the central field was calculated from the differential light 
sensitivity and summed to give the total number for the given quadrant. The number of 
remaining ganglion cell axons at each corresponding stimulus location was calculated from the 
PPRNFL thickness and summed to give the quadrant total. The topographical relationship 
between each stimulus location and the corresponding position of the axonal entry at the optic 
nerve head followed that of an established model [37]. 
The visual field and PPRNFL outcomes of the normal individuals, applied to each model, were 
separately adjusted to the age of the individuals exposed to vigabatrin based upon the respective 
slopes of the relationships with age [38-39].    
2.5 Analysis 
The characteristics of those with and without VAVFL were described with summary statistics. 
Differences in a given summary statistic were evaluated, as appropriate, using Analysis of 
Variance and/ or Co-variance and/ or independent t-tests for continuously distributed variables 
and Chi-square or Fishers Exact tests for categorical variables.  
The structure-function relationships for the two models were illustrated by separate scatter 
plots. For the Hood model, the confidence intervals associated with the asymptote were 
calculated from the medians of 100,000 samples generated by statistical bootstrapping.  For 
the Harwerth model, any differences between the three groups in the relationship between the 
remaining ganglion cell soma and the remaining axons were investigated using Principal 
Component Analysis. Briefly, two successive linear transformations were undertaken of the 
relationship. The first translation was undertaken such that the origin coincided with the means 
of the values along the x- and along the y-axes. The second translation involved rotation of the 
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10
axes such that the x-axis coincided with the line of best linear fit through the data. The first 
principal component enabled an estimate of the total number of retinal ganglion cells based 
upon the soma and axon estimates. The second principal component described the similarity 
between the three groups in the relationship between the estimates of the soma and axon 
quantities. This latter component increased with increase in the disparity between the two 
estimates; a higher number indicated a greater estimate of soma. The differences in the 
distribution of each component between the three groups were evaluated using the Mann-
Whitney Test. 
The correlations between the estimated number of remaining ganglion cell soma and axons and 
the duration and cumulative dose of vigabatrin were determined by Pearson Product Moment 
Correlation.    
The datasets generated during and/ or analysed during the current study are available from the 
corresponding author on reasonable request. 
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3.0 Results 
3.1 Cohort demography 
The demographic characteristics of the cohort exposed to vigabatrin are shown in Table 1. The 
cohort contained more females than males (χ2 = 6.4; p=0.026). The males were slightly older 
than the females at the time of perimetry and OCT but this difference did not reach statistical 
significance (difference between means 4.26 years 95% CI -4.65 to 11.18; p=0.840). Twenty-
four of the 40 individuals exhibited VAVFL. All but one of these 24 individuals exhibited 
visual field loss within the central field. The difference in the proportion with VAVFL by 
gender, 11 out of 15 males and 13 out of 25 females, was not statistically significant (p=0.188). 
The age of the individuals with VAVFL at the time of perimetry and OCT was identical to 
those exposed to vigabatrin but with normal fields (difference between means -0.24 years, 95% 
CI -7.77 to 7.30; p=0.952). The duration and cumulative dose of vigabatrin therapy were highly 
correlated (r=0.849, p<0.001). Those with VAVFL manifested a greater exposure to vigabatrin 
(difference between means 6.27kg, 95% CI 3.11 to 9.40, p<0.003; and 4.95 years, 95% CI 2.02 
to 7.88; p<0.001) and a shorter time from withdrawal (difference between means -4.1 years, 
95% CI -6.49 to -1.71; p<0.001).  
The functional and structural characteristics of the cohort exposed to vigabatrin, averaged 
across the two eyes, are shown in Table 2. The two most common summary measures for 
describing the severity of central visual field loss, the Mean Deviation and the Pattern Standard 
Deviation, were each similar between the right and left eyes (p=0.34) and were worse in each 
eye (p<0.001) for the individuals with VAVFL than for those without the toxicity. The 
difference between the means of those with and without VAVFL for the two eyes, combined, 
was -7.59dB (95% CI -8.96 to -1.37; p<0.001) and 5.91dB (95% CI 4.90 to 7.33 p<0.001) 
respectively.   
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12
The thickness of the PPRNFL was similar between the right and left eyes (p=0.08), varied 
between quadrants (p<0.001) and was thinner in each eye for the individuals with VAVFL than 
for those without the toxicity and was thickest for the normal individuals (p<0.001). The overall 
PPRNFL, for the two eyes combined, was substantially thinner for those with VAVFL than for 
those without (difference between means -86.4µm, 95% CI -110.0 to -62.8; p<0.001). The 
overall PPRNFL for those without the toxicity was thinner than that for the normal individuals 
even though the latter exhibited additional thinning due to the older age: for the overall 
thickness of the two eyes combined, the difference in the means was -37.3µm (95% CI -65.2 
to 9.4; p<0.001).  
3.2 Hood Model
The relationship between the PPRNFL thickness and the mean Total Deviation, relative to the 
exponential function (solid line), for the superior and inferior quadrants for each individual in 
each of the three groups is given in Figure 1 for the right and left eyes, separately. The 
asymptotes, and the corresponding 95% confidence intervals, for the superior and inferior 
quadrants of the right eye were 59.9µm (53.0 to 78.3) and 62.4µm (47.0 to 82.0), respectively, 
and for the left eye 67.4µm (50.0 to 85.3) and 68.8µm (60.5 to 75.8). 
3.3 Harworth Model 
The relationship between the remaining ganglion cell soma and the remaining ganglion cell 
axons for the superior and inferior meridians for each individual in each of the three groups is 
given in Figure 2 for the right and left eyes, separately. The estimated number of remaining 
ganglion cell soma was greater than that for the remaining ganglion cell axons.  
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13
The outcome of the principal components analysis of the relationship given in Figure 2 is 
shown in Figure 3. Those with VAVFL exhibited fewer remaining ganglion cells derived from 
the corresponding combined estimates of the soma and axons (i.e., a lower value along the First 
Principal Component) in each of the two quadrants for each eye, compared to those exposed to 
vigabatrin but with normal fields (all p≤0.001) and also compared to the normal individuals 
(all p≤0.001).  Those exposed to vigabatrin with normal fields had fewer ganglion cells than 
the normal individuals (p≤0.001 to p<0.05).  There was no difference between the three groups 
in the relationships between the two estimates of the ganglion cell characteristics (i.e., along 
the Second Principal Component). 
3.4 Correlation with vigabatrin exposure 
The Coefficients of Determination between the estimates of the remaining soma and axons for 
the superior and inferior quadrants and the cumulative dose and duration of vigabatrin therapy, 
at the time of detection of the field loss, are given in Table 4. Almost all the Coefficients were 
higher for cumulative dose than for duration and were highest (approximately 42%) both for 
the Total Deviation and for the estimated number of remaining axons. 
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4.0 Discussion 
This study provides the first quantitative confirmation of the topographical correspondence 
between the central visual field and the PPRNFL outcomes in vigabatrin toxicity. Both models 
yielded strong function-structure relationships, similar to those for other optic neuropathies 
[29-32], and validated each model to the other. Such outcomes indicate that, in individuals with 
vigabatrin toxicity, perimetry and OCT of the PPRNFL implicate the same underlying 
dysfunction, i.e., retinal ganglion cell abnormality.  
The fundamental strength of the study lies in the extensive range of exposure to vigabatrin 
(0.33 to 16.1 years) and of severity of VAVFL (MD -1.62 to -22.81; PSD 2.65 to 13.04); such 
ranges provide an unequivocal insight into the effect of the toxicity over the longer term.  
The outcome from the Hood model demonstrates the impact of the non-axonal component of 
OCT reflectance on the management of vigabatrin toxicity. An assessment of the severity of 
the PPRNFL thickness, when expressed in µm, was only possible where the equivalent visual 
field loss was within a mean Total Deviation of approximately -10.0dB after which the value 
of the PPRNFL thickness reached an asymptote. In the current study, 9 of the 24 individuals 
with VAVFL exhibited mean Total Deviations of worse than -10.0dB in both quadrants of each 
eye.  
The Harwerth model empirically overcomes the non-axonal component of reflectance by the 
use of a correction factor, based upon the mean Total Deviation. It expresses the PPRNFL 
thickness as a continuous scale in terms of the number of remaining axons and enables an 
assessment of the full range of PPRNFL thinning associated with vigabatrin toxicity. The 
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15
overestimation of the number of remaining ganglion cell soma in each quadrant compared to 
the number of remaining axons was similar to that for primary open-angle glaucoma 29 and is 
a limitation of the model [40].  
The definition of vigabatrin retinal toxicity was based upon the outcome of perimetry rather 
than of OCT.  All 24 individuals exhibited the characteristic pattern of PPRNFL thinning 
associated with vigabatrin toxicity [13-18]. Of these, two exhibited temporal quadrant thinning 
in association with severe VAVFL. 
Of the 16 individuals without VAVFL, 8 exhibited a normal PPRNFL thickness in each eye 
for each of the four quadrants relative to the age-corrected normal values proprietary to the 
manufacturer. Three individuals exhibited bilateral and symmetrical abnormal PPRNFL 
thinning in either the superior or inferior quadrants, only, which lay at the fifth or lower 
percentiles of the proprietary normal values. Such a pattern of thinning is associated with 
vigabatrin toxicity [13-18] and may have been an earlier marker than the field loss.  The 
remaining five individuals each exhibited abnormal thinning (between the fifth and first 
percentiles) in one randomly distributed quadrant of one eye. Such an outcome was not 
associated with visual field loss and was most likely to have arisen from the difficulty in 
achieving quality fixation during the scan acquisition. This is a common problem in individuals 
with severe epilepsy. Nevertheless, as a group, the PPRNFL thicknesses were statistically 
significantly thinner than those for the normal individuals.  Such a finding is in accord with the 
outcome reported in drug resistant epilepsy [20].  
All 11 individuals exhibited normal visual fields and normal PPRNFL thicknesses, defined in 
terms of probability/ percentile analyses relative to the distributions of the age-corrected 
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normal values proprietary to each type of instrument, thereby confirming the validity of the 
authors’ review procedure. 
The Coefficient of Determinations between the cumulative dose and duration of vigabatrin and 
the various estimates of function and structure were modest and are compatible with the 
concept of an idiopathic drug reaction [16-17]; however, it was clear that functional and 
structural damage unquestionably worsened with increase in exposure to vigabatrin. This latter 
finding is compatible with cross-sectional evidence that the risk of developing vigabatrin 
toxicity increases with increasing exposure to vigabatrin [11-12]. Such relationships further 
underline the importance of regular assessments of individuals undergoing therapy with 
vigabatrin.   
Both models are based upon the presence of VAVFL manifesting within the central field. 
However, it should be remembered that VAVFL is a peripheral defect which subsequently 
encroaches, to varying extents, into the central field. Both models are also dependent upon the 
overall differential light sensitivity, i.e. that arising from both the optical quality and the 
integrity of the neural processing.  The attenuation due to optical degradation was minimized 
by excluding those manifesting a cataract, or other disturbances of the ocular media, from the 
case series and by ensuring that the appropriate refractive correction was used for the viewing 
distance of the perimeter. Optical degradation worsens the Total Deviation outcome utilized in 
the Hood model and erroneously decreases, by similar magnitudes, the estimated numbers of 
ganglion cell soma and axons in the Harwerth model.  However, toxicity encroaching into the 
central field can still be identified by perimetry in the presence of optical degradation since the 
diagnosis is based upon the characteristic shape of the field loss manifested by Pattern 
Deviation probability analysis.  
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Both models were developed from the outcomes of the visual field examination with the 
Humphrey Field Analyzer and of OCT with the StratusOCT; both of these instruments were 
used in the current study. The models have subsequently been successfully applied, in primary 
open-angle glaucoma, to the outcome from spectral domain OCT [40] which has superseded 
time domain OCT.  Compared to time domain OCT, spectral domain OCT exhibits improved 
axial and lateral resolution, by approximately 5µm, and a faster B scan acquisition time; but a 
relative reduction in detector performance. In addition, most spectral domain systems also 
incorporate software to compensate for poorly aligned images. However, the operator 
variability is similar [41] and the PPRNFL thickness by each technique gives similar 
sensitivities and specificities for the detection of early to moderate primary open-angle 
glaucoma [42-43] and for multiple sclerosis [44], retrobulbar optic neuritis and non-arteritic 
ischemic optic neuropathy [45]. The use of spectral domain OCT in the current study would 
merely have resulted in slight instrument-dependent differences in the absolute thickness of the 
PPRNFL [41, 45]. Such differences would not have materially affected the strong relationship 
between function and structure in vigabatrin toxicity which has been demonstrated in the 
current study. 
5.0 Conclusion 
Perimetry enables an assessment of the severity of vigabatrin toxicity regardless of the extent 
of PPRNFL thinning. When OCT is used as the primary investigative modality and thinning is 
suspected, a concurrent peripheral and central visual field examination should be undertaken, 
whenever possible, to confirm the presence of VAVFL. The severity of vigabatrin toxicity can 
only be directly assessed by OCT when the superior and/ or inferior quadrant PPRNFL 
thicknesses are greater than approximately 65µm, depending upon the type of tomographer. 
Below this value (equivalent to a quadrant Total Deviation within the central field of worse 
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than approximately -10.0dB) severity can only be evaluated in terms of the number of 
remaining axons, an outcome dependent on perimetry.  
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EXPOSED TO VIGABATRIN NORMAL 
          INDIVIDUALS 
VAVFL Normal 
Gender  Male  11  4   6 
   Female 13  12   5 
Age (Yrs)  Mean  43.6  43.8   72.1 
SD  12.9  10.5   15.1
Median 44.3  45.5   72.1 
IQR  32.3, 52.0 38.9, 50.0  59.8, 77.8 
Range  22.8 to 68.6 19.0 to 60.2  30.9 to 81.5 
Cumulative dose Mean  10.6  4.3 
of vigabatrin (kg) SD  5.2  4.6
   Median 11.0  2.4 
   IQR  6.7, 14.4 5.2, 14.2  
   Range  2.5 to 19.4 0.69 to 14.2 
Duration of  Mean  10.9  5.9  
vigabtrin (Yrs) SD  3.4  5.0 
   Median 11.7  5.1 
IQR  9.2, 13.4  9.0, 14.5 
Range  3.6 to 16.1 0.33 to 14.5 
Time from  Mean  6.6  10.7 
withdrawal of SD  2.6  4.3  
vigabatrin (Yrs) Median 6.5  8.9 
   IQR  5.4, 7.3 8.1, 13.4 
   Range  0.3 to 12.6 4.7 to 19.2
Table 1 The summary statistics for the demographic characteristics of the 40 individuals 
exposed to vigabatrin by visual field outcome and for the normal individuals  
VAVFL vigabatrin-associated visual field loss 
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EXPOSED TO VIGABATRIN NORMAL
     INDIVIDUALS 
VAVFL  Normal  
   Visual field 
Mean Deviation Mean  -8.96   -1.37  0.09 
(dB)   SD  6.17   1.79  1.17
Median -7.58   -0.89  -0.08 
IQR  -12.06, -3.95  -2.23, -0.12 -062, 1.05 
Range  -22.81 to -1.62 -5.1 to 0.78 -1.91 to 1.85 
Pattern Standard Mean  8.21   2.30  1.53 
Deviation (dB) SD  3.37   0.49  0.33
   Median 8.22   2.16  1.47 
   IQR  5.03, 11.50  1.89, 2.64 1.29, 1.72 
   Range  2.65 to 13.04  1.59 to 3.7 0.96 to 2.34 
PPRNFL thickness  
(µm) 
Superior  Mean  68.1   97.3  116.0 
SD  15.1   14.7  17.5   
   Median 71.2   96.0  113.2 
IQR  57.5, 79.2  88.6, 106.4 103.0, 127.4 
Range  27.0 to 95.7  67.0 to 140.0 85.0 to 158.0 
Inferior  Mean  77.3   105.8  114.3  
SD  18.4   11.1  17.1 
   Median 79.9  106.2  112.0 
IQR  65.2, 88.1  101.0, 113.5 103.25. 127.4 
Range  22.9 to 128.5  81.3 to 125.3 72.0 to 137.0 
Nasal   Mean  38.6   62.0  69.3 
SD  10.2   10.8  16.4 
   Median 37.5   61.5  66.8 
IQR  31.9, 47.0  56.8, 70.2 56.1, 80.0  
Range  3.0 to 60.0  42.0 to 86.0 46.5 to 109.0 
Temporal  Mean  64.3   68.6  72.5 
SD  12.8   10.6  12.5 
   Median 64.0   61.5  74.8 
IQR  54.8, 73.0  56.8, 70.2 64.8, 78.6  
Range  39.0 to 104.0  50.0 to 89.3 49.0 to 106.0 
Table 2 The summary statistics for the visual field and the PPRNFL for the 40 individuals 
exposed to vigabatrin by visual field outcome and for the normal individuals. Note: the Mean 
Deviation, the Pattern Standard Deviation and the PPRNFL thicknesses were each not 
significantly different between the right and left eyes and, for brevity, each outcome, is given 
for the two eyes, combined.  
VAVFL vigabatrin-associated visual field loss, PPRNFL peripapillary retinal nerve fibre layer 
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DURATION (Yrs) CUMULATIVE DOSE (Kg)
Right Left Right Left
Total Deviation 
  Superior 23.7 20.1 44.6 40.7
Inferior 21.3 21.3 37.0 37.8
Number of  
remaining soma 
Superior 23.7 21.0 34.9 36.1
  Inferior 12.5  19.3  24.8  26.9 
PPRNFL    
  Superior 35.8  33.8  30.2  26.4  
  Inferior 23.5  21.7  34.5  29.2 
Number of  
remaining axons 
  Superior 40.5  36.5  43.8  39.7  
  Inferior 29.2  27.8  37.8  36.5
Table 3 The Coefficient of Determination (R2), expressed as a percentage, for the linear 
correlation between the various outcomes of perimetry and of optical coherence tomography 
and the duration and cumulative dose of vigabatrin    
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FIGURE LEGENDS 
Fig 1 The outcome of the Hood model: the peripapillary retinal nerve fibre layer thickness 
against the mean Total Deviation for the right (left column) and left (right column) eye. The 
solid line indicates the exponential function. Top: superior quadrant. Bottom: inferior quadrant. 
The Coefficient of Determination, R2, for each function is given in the top left of each panel 
Fig. 2 The outcome of the Harwerth model: the estimated number of remaining retinal ganglion 
cell soma against the estimated number of remaining ganglion cell axons for the right (left 
column) and left (right column) eye. Top: superior quadrant. Bottom: inferior quadrant  
Fig. 3 The outcome of the Principal Components analysis of the number of remaining retinal 
ganglion cell soma and the number of remaining ganglion cell axons for the right (left column) 
and left (right column) eye. Top: superior quadrant. Bottom: inferior quadrant 
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Figure 1 Click here to download Figure Wild_Figure 1.tif 
Figure 2 Click here to download Figure Wild_Figure 2.tif 
Figure 3 Click here to download Figure Wild_Figure 3.tif 
ON LINE SUPPORTING INFORMATION 
1.0 APPENDIX 1 
The model of Hood [1] is defined as:  
R= so10
0.1 x D + b for D≤0
and  R= so+b for D≥0
where R is the PPRNFL thickness for the given quadrant, D is the mean of the Total Deviation 
value for the corresponding quadrant in Program 24-2 format; so is the median of the PPRNFL 
thickness for individuals with D≤-10dB, b is the remaining thickness arising from glial tissue 
etc, and so + b is the mean thickness of the normal individuals.  
Reference 
1. Hood DC. Relating nerve fiber layer thickness to behavioural sensitivity in patients with
glaucoma. The application of a linear mode. J Opt Soc Am 2007;24(5):1426-1430.
2.0 APPENDIX 2 
Ganglion cell soma quantity 
The total number of retinal ganglion cell soma, gcSAP,, across the given number of stimulus 
location arranged in Program 24-2 format of the Humphrey Field Analyzer, was calculated 
using the equations of Wheat et al [1]: 
 m = [0.054*(ecc*1.34)] + 0.9 (1)
 b = [-1.5*(ecc*1.34)] -14.8 (2)
 gl = {[(s - 1) – b] / m} + 4.7   (3) 
 and  
 gcSAP= Σ10˄ (gl*0.1)    (4) 
where m and b represent the slope and intercept, respectively, of the linear function of ganglion 
cell density (gl) by differential light sensitivity at the given eccentricity (ecc); and where gl, 
expressed as the number of soma per mm2 of retina, and the differential light sensitivity (s), are 
each given in dB. 
The constant, -1, in Equation (3) accounts for the approximate 1dB higher sensitivity of the 
SITA Standard algorithm compared to the Full Threshold algorithm [2-4] and was used for the 
calculation of the ganglion cell soma quantity for the individuals with primary open-angle 
glaucoma. The constant was omitted for the calculation of the ganglion cell soma quantity for 
the individuals exposed to vigabatrin since the differential light sensitivities obtained with the 
Full Threshold and FASTPAC algorithms are clinically identical [3-4].  The constant 4.7 in 
Equation (3) converts retinal ganglion cell soma density to the total number of retinal ganglion 
cell somas at the given stimulus location based upon the 6° square stimulus grid of Program 
24-2.  
The ganglion cell soma quantities derived by standard automated perimetry at each stimulus 
location were then summed, as appropriate, to give the global and each oblique quadrant total, 
based upon the topographical map of Garway-Heath et al 2000) [5] which relates the axons of 
the retinal ganglion cells sub-serving the given perimetric stimulus location to their entry point 
at the optic nerve head. 
where m and b represent the slope and intercept, respectively, of the linear function of ganglion 
cell density (gl) by differential light sensitivity at the given eccentricity (ecc); and where gl, 
expressed as the number of soma per mm2 of retina, and the differential light sensitivity (s), are 
each given in dB. 
The constant, -1, in Equation (3) accounts for the approximate 1dB higher sensitivity of the 
SITA Standard algorithm compared to the Full Threshold algorithm [2-4] and was used for the 
calculation of the ganglion cell soma quantity for the individuals with primary open-angle 
glaucoma. The constant was omitted for the calculation of the ganglion cell soma quantity for 
the individuals exposed to vigabatrin since the differential light sensitivities obtained with the 
Full Threshold and FASTPAC algorithms are clinically identical [3-4].  The constant 4.7 in 
Equation (3) converts retinal ganglion cell soma density to the total number of retinal ganglion 
cell somas at the given stimulus location based upon the 6° square stimulus grid of Program 
24-2.  
The ganglion cell soma quantities derived by standard automated perimetry at each stimulus 
location were then summed, as appropriate, to give the global and each oblique quadrant total, 
based upon the topographical map of Garway-Heath et al 2000) [5] which relates the axons of 
the retinal ganglion cells sub-serving the given perimetric stimulus location to their entry point 
at the optic nerve head. 
Ganglion cell axon quantity 
The ganglion cell axon quantity derived by optical coherence tomography was calculated for 
the superior and inferior quadrants using the additional equations of Wheat et al [1] developed 
with the StratusOCT:
 d = (-0.007*age) + 1.4 
 a = mh*px*21.1*d 
 c = (-0.28*mTD) + 0.18 
 and  
 axoct = 10
˄[([(log a)*10] - c)/10]
where d is the axonal density, i.e. the number of axons per μm2; age is in years, a is the number 
of axons for a section of the RNFL scan with a mean height (mh) in μm over px number of 
pixels; 21.2 is the length per pixel in μm for the 10.87 mm scan length of the standard RNFL 
(3.4) Scan protocol of the Stratus OCT; c is a correction factor in dB for the non-axonal 
component of the measured retinal nerve fibre layer thickness at the given stage of the disease, 
expressed by the mean of the Total Deviation values for the given visual field sector; and axoct 
is the age-corrected and non-axonal component-corrected total number of retinal ganglion cell 
axons in the given sector of the PPRNFL.  
References 
1. Wheat JL, Rangaswamy NV, Harwerth RS. Correlating RNFL thickness by OCT with 
perimetric sensitivity in glaucoma patients. J Glaucoma 2012;21(2):95-101. 
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